Weiss J, Elsbach P, Shu C, Castillo J, Grinna L, Horwitz A, Theofan G
Department of Microbiology, New York University School of Medicine, New York 10016.
J Clin Invest. 1992 Sep;90(3):1122-30. doi: 10.1172/JCI115930.
The bactericidal/permeability-increasing protein (BPI) of neutrophils and BPI fragments neutralize the effects of isolated Gram-negative bacterial lipopolysaccharides both in vitro and in vivo. Since endotoxin most commonly enters the host as constituents of invading Gram-negative bacteria, we raised the question: Can BPI and its bioactive fragments also protect against whole bacteria? To determine whether the bactericidal and endotoxin-neutralizing activities of BPI/fragments are expressed when Gram-negative bacteria are introduced to the complex environment of whole blood we examined the effects of added BPI and proteolytically prepared and recombinant NH2-terminal fragments on: (a) the fate of serum-resistant encapsulated Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa that survive the antibacterial actions of whole blood and (b) the ability of these bacteria to trigger cytokine release. Added BPI in nanomolar concentrations killed each of three encapsulated strains of E. coli and in closely parallel fashion inhibited tumor necrosis factor (TNF) release. Holo-BPI and its NH2-terminal fragment were equipotent toward a rough LPS chemotype K1-encapsulated strain, but the fragment was substantially more potent than holo-BPI toward two encapsulated smooth LPS chemotype strains. TNF release induced by K. pneumoniae and P. aeruginosa was also inhibited by both holo-BPI and fragment but, at the protein concentrations tested, P. aeruginosa was killed only by the fragment and K. pneumoniae was not killed by either protein. The bactericidal action of BPI/fragment toward E. coli is inhibited by C7-depleted serum, but accelerated by normal serum, indicating that BPI, acting in synergy with late complement components, enhances extracellular killing of serum-resistant bacteria. Thus, BPI and an even more potent NH2-terminal fragment may protect against Gram-negative bacteria in the host by blocking bacterial proliferation as well as endotoxin-mediated effects, not only as components of the intracellular antibacterial arsenal of the neutrophil, but also as potentially therapeutic extracellular agents.
中性粒细胞的杀菌/通透性增加蛋白(BPI)及其片段在体外和体内均可中和分离出的革兰氏阴性菌脂多糖的作用。由于内毒素最常作为入侵革兰氏阴性菌的成分进入宿主,我们提出了一个问题:BPI及其生物活性片段能否也抵御完整细菌?为了确定当革兰氏阴性菌被引入全血的复杂环境时BPI/片段的杀菌和内毒素中和活性是否会表现出来,我们研究了添加的BPI以及经蛋白水解制备的和重组的氨基末端片段对以下方面的影响:(a)能在全血的抗菌作用下存活的血清抗性荚膜大肠杆菌、肺炎克雷伯菌和铜绿假单胞菌的命运,以及(b)这些细菌触发细胞因子释放的能力。纳摩尔浓度的添加BPI杀死了三种荚膜大肠杆菌菌株中的每一种,并以非常相似的方式抑制肿瘤坏死因子(TNF)的释放。全BPI及其氨基末端片段对粗糙脂多糖化学型K1荚膜菌株的作用相当,但该片段对两种荚膜光滑脂多糖化学型菌株的作用比全BPI强得多。肺炎克雷伯菌和铜绿假单胞菌诱导的TNF释放也受到全BPI和片段的抑制,但在所测试的蛋白浓度下,铜绿假单胞菌仅被片段杀死,肺炎克雷伯菌则未被任何一种蛋白杀死。BPI/片段对大肠杆菌的杀菌作用受到C7缺失血清的抑制,但受到正常血清的加速,这表明BPI与补体晚期成分协同作用,增强了对血清抗性细菌的细胞外杀伤作用。因此,BPI和一种甚至更有效的氨基末端片段不仅作为中性粒细胞细胞内抗菌武器库的组成部分,而且作为潜在的治疗性细胞外制剂,可能通过阻止细菌增殖以及内毒素介导的作用来保护宿主免受革兰氏阴性菌的侵害。